Thyroid Cancer Clinical Trial
Official title:
Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident
Verified date | March 2020 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Iodine-131(131I) and other radioisotopes of Iodine are contained in fallout from atmospheric
nuclear weapons tests and are among the radionuclides most likely to be released in a nuclear
reactor accident. In spite of nearly 50 years of experience, the risk of thyroid disease,
especially thyroid cancer, attributable to exposure to 131I remains unknown, although the
carcinogenic potential of x-ray and gamma-ray exposure of the thyroid is reasonably well
known. The available data also indicate that children face greater risks of radiation-induced
thyroid cancer than do adults.
The nuclear power plant accident at Chernobyl released large quantities of 131I and other
radioisotopes of iodine into the atmosphere, contaminating thousands of square kilometers and
exposing millions of people. It is proposed that a well-defined subset of Belarussian
children aged 0-18 years at the time of the accident be examined by well-trained specialists
for thyroid disease at least biennially for up to 30 years. A cohort of 15,000 children has
been identified, all of whom had their thyroids measured for radioactivity during the weeks
immediately following the accident. Under a rigid research protocol these children will
receive complete diagnostic thyroid examinations, including palpation, ultrasound scanning,
thyroid hormone and other laboratory tests, and fine-needle aspiration, as appropriate.
Cancer will be determined by expert pathology examination of tissue. In addition to the
analysis of thyroid radiation measurements made in May-June, 1986, efforts will be made to
reconstruct each person's exposure and to estimate the radiation doses to the thyroid. This
will involve the reconstruction of deposition patterns and environmental pathways of the
radioiodines, and of the location, dietary characteristics, and lifestyle of each person
throughout the exposure period.
The data will be analyzed to evaluate the relationship, if any, between thyroid disease,
especially cancer, and the radiation dose to the thyroid, with emphasis on the dose from
131I. The primary focus will be on dose-response analyses of person-year incidence data with
stratification by sex, age at exposure, geographic area, time, and age at risk. Confounding
factors, e.g., use of potassium iodide (KI) as a prophylactic measure, will be evaluated and
controlled in the analysis, and the uncertainty of the dose estimates will be taken into
account.
In addition to producing risk coefficients for thyroid cancer and other thyroid diseases in
children as a function of sex and age at the time of exposure, it is expected that the
analyses will contribute new knowledge of the carcinogenic effectiveness of 131I in
comparison with that of x-ray and gamma radiation. This information will fill a major gap in
the world's knowledge of radiation effects, and will provide guidance for radiation
protection and public health policies wherever nuclear reactors are in operation.
Status | Completed |
Enrollment | 19456 |
Est. completion date | March 11, 2020 |
Est. primary completion date | March 11, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 51 Years |
Eligibility |
- INCLUSION CRITERIA: We will include about 3,000 individuals born in Belarus from April, 26, 1986 through March, 31, 1987 who were exposed to internal and external sources of ionizing radiation during prenatal and early postnatal periods due to the Chernobyl fallout. EXCLUSION CRITERIA: For the purpose of individual dose reconstruction we need to establish child-mother pair for each cohort member and conduct personal dosimetric interview with child s mother. We anticipate that some of the eligible subjects will be deceased at the time of the cohort construction. Deceased subjects will not be included in the cohort. Excluded from the interview study and the subsequent follow-up study will be those who are deceased, cannot be located, refuse to participate in the study, or do not provide informed consent. |
Country | Name | City | State |
---|---|---|---|
Belarus | Republican Resear ch Center for Radiation Medicine and Human Ecology | Gomel | |
Belarus | Ministry of Health Republic of Belarus | Minsk |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
Belarus,
Drozdovitch V, Minenko V, Golovanov I, Khrutchinsky A, Kukhta T, Kutsen S, Luckyanov N, Ostroumova E, Trofimik S, Voillequé P, Simon SL, Bouville A. Thyroid Dose Estimates for a Cohort of Belarusian Children Exposed to (131)I from the Chernobyl Accident: Assessment of Uncertainties. Radiat Res. 2015 Aug;184(2):203-18. Epub 2015 Jul 24. — View Citation
Little MP, Kwon D, Zablotska LB, Brenner AV, Cahoon EK, Rozhko AV, Polyanskaya ON, Minenko VF, Golovanov I, Bouville A, Drozdovitch V. Impact of Uncertainties in Exposure Assessment on Thyroid Cancer Risk among Persons in Belarus Exposed as Children or Adolescents Due to the Chernobyl Accident. PLoS One. 2015 Oct 14;10(10):e0139826. doi: 10.1371/journal.pone.0139826. eCollection 2015. — View Citation
Zablotska LB, Nadyrov EA, Polyanskaya ON, McConnell RJ, O'Kane P, Lubin J, Hatch M, Little MP, Brenner AV, Veyalkin IV, Yauseyenka VV, Bouville A, Drozdovitch VV, Minenko VF, Demidchik YE, Mabuchi K, Rozhko AV. Risk of thyroid follicular adenoma among children and adolescents in Belarus exposed to iodine-131 after the Chornobyl accident. Am J Epidemiol. 2015 Nov 1;182(9):781-90. doi: 10.1093/aje/kwv127. Epub 2015 Oct 5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Radiation-related risk of benign and malignant thyroid disease | radiation risk estimate | 2-3 years after initiation of study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |